MS
NICE wants more Lemtrada data
December 6, 2013Sales and Marketing Lemtrada, MS, NICE, Sanofi
NICE has said there are ‘still questions to be answered’ over Sanofi’s submission of its multiple sclerosis drug Lemtrada and …
‘Fatal’ safety concerns throw doubt on Lemtrada
November 11, 2013Research and Development, Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi
An FDA committee has dashed hopes of an approval for Sanofi’s multiple sclerosis drug after saying its benefits may not …
NICE: we need more Aubagio data
September 18, 2013Sales and Marketing Aubagio, Genzyme, MS, NICE, Sanofi
Sanofi’s Lemtrada given European go ahead
September 18, 2013Research and Development, Sales and Marketing Aubagio, Lemtrada, MS, Sanofi, gilenya
GSK fires head of China research over data fraud
June 11, 2013Research and Development China, GSK, Jingwu Zang, MS, autoimmune
GlaxoSmithKline has dismissed its vice president of research in China in connection with ‘misrepresentation’ of research data.Jingwu Zang had been senior …
Novartis works in MS switch
June 11, 2013Research and Development, Sales and Marketing MS, Novartis, gilenya
Novartis’ oral MS drug Gilenya has been found to help multiple sclerosis (MS) patients who switch to it after taking …
Charity: MS treatment is ‘lottery’
May 1, 2013Sales and Marketing MS, lottery, society
Multiple sclerosis care in the UK is a ‘lottery’ according to research by the MS Society. The charity says that …
Multiple sclerosis rivals gain EU approval
March 27, 2013Research and Development, Sales and Marketing Biogen IDEC, Genzyme, MS
Rival MS treatments from Biogen Idec and Genzyme have both received European approval. The CHMP has recommended marketing authorisation for …
Biogen and Elan file for Tysabri first line use in MS
January 18, 2013Sales and Marketing Biogen IDEC, EMA, Elan, FDA, MS, Tsyabri, gilenya
Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …
Sanofi criticised for multiple sclerosis manoeuvres
November 2, 2012Sales and Marketing Cancer, Lemtrada, MS, Sanofi
Sanofi is facing a backlash as it prepares its new MS treatment for the market. Lemtrada (alemtuzumab) has produced very …
Novartis’ MS drug improves outcomes
October 15, 2012Sales and Marketing MS, Novartis, gilenya
Novartis’ multiple sclerosis (MS) drug Gilenya has demonstrated what the manufacturer calls ‘significant’ benefits for patients if used early. Results …
Genzyme ‘confident’ of FDA nod for MS drug
August 29, 2012Sales and Marketing Genzyme, Lemtrada, MS, multiple sclerosis
Genzyme insists it is on course to resubmit an existing oncology drug for the treatment of relapsing multiple sclerosis (RMS), …
Sanofi submits key MS pill for approval
June 12, 2012Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi
Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …
Merck KGaA swings axe over Serono operations
April 25, 2012Manufacturing and Production, Research and Development, Sales and Marketing Cladribine, MS, Merck KGaA, Switzerland, job cuts
Merck KGaA will cut around 500 jobs from its pharmaceutical unit in Switzerland, the firm has announced. The company said …
NICE U-turn sees Gilenya MS pill recommended
March 16, 2012Sales and Marketing MS, NICE, UK, fingolimod, gilenya
NICE has changed its mind on Novartis’ multiple sclerosis pill Gilenya, and is now recommending the drug in a subgroup …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
